AbbVie Lowers Q1 & Full-Year EPS Guidance by $0.41 Due to $744M IPR&D Expense
Summary
AbbVie updated its Q1 and full-year 2026 adjusted diluted EPS guidance, lowering both by $0.41 per share due to a $744 million pre-tax acquired IPR&D and milestones expense.
Key Events
-
Revised Q1 2026 EPS Guidance
AbbVie's first quarter 2026 adjusted diluted EPS guidance range, including the impact of acquired IPR&D and milestones expense, is now $2.56 - $2.60, down from the previously announced $2.97 - $3.01.
-
Revised Full-Year 2026 EPS Guidance
The full-year 2026 adjusted diluted EPS guidance range, including the impact of first quarter acquired IPR&D and milestones expense, is now $13.96 - $14.16, reduced from the prior range of $14.37 - $14.57.
-
Significant IPR&D Expense
The revisions are primarily due to an expected $744 million pre-tax acquired IPR&D and milestones expense incurred in the first quarter of 2026, which unfavorably impacts EPS by $0.41.
Analysis
AbbVie has updated its financial guidance for both the first quarter and the full year of 2026, reflecting a significant pre-tax acquired IPR&D and milestones expense of $744 million. This expense directly reduces both GAAP and adjusted non-GAAP diluted earnings per share guidance by $0.41. Investors should note this downward revision from the previously announced guidance, as it impacts the company's near-term and annual profitability outlook. While IPR&D expenses are part of pharmaceutical R&D, the magnitude of this specific charge warrants attention.
At the time of this filing, ABBV was trading at $208.27 on NYSE in the Life Sciences sector, with a market capitalization of approximately $369.3B. The 52-week trading range was $164.39 to $244.81. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.